121results about "Tetrapeptides" patented technology

Compositions and methods for treating diseases associated with dysregulation of miR-21, particularly cancer, are disclosed.

The present invention relates to an antibody conjugate that is particularly suitable for targeting Trop-2 expressing cells, especially tumor cells. The antibody conjugate according to the invention has the structure (1), where AB is an antibody capable of targeting Trop-2 expressing tumors, L is a linker connecting Z to D, Z is a connecting group, and L 6 -GlcNAc(Fuc) w -(G) j -S-(L 7 ) w’ -, in which G is a monosaccharide, j is an integer ranging from 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, Fuc is fucose, w is 0 or 1, w' is 0, 1, or 2, and L 7 is -N(H)C(O)CH2-, -N(H)C(O)CF2-, or -CH2-, D is exatecan, b is 0 or 1, x is 1 or 2, and y is 1, 2, 3, or 4. The present invention further relates to methods for preparing the antibody conjugates of structure (1) and applications of the antibody conjugates of structure (1).

The present invention provides biomolecular glass and its use. The biomolecular glass is obtained by volatilizing a solvent from a solution of biomolecular raw materials, the solution of biomolecular raw materials comprising biomolecular raw materials, a modifier, and a solvent. The biomolecular raw materials include natural amino acids, peptides, amino acid derivatives, peptide derivatives, or mixtures of two or more of the above. The soluble biomolecular glass of the present invention has excellent biocompatibility, high light transmittance, good mechanical strength, flexible processability, and biodegradability, and can be processed into implantable or non-implantable medical materials and / or devices, fillers and stent materials, electronic sensing materials and / or devices, temporary electronic materials and / or devices, etc., and can be decomposed by living organisms or nature, with decomposition products being non-contaminating.

To provide a method for producing a high-purity peptide compound in a high yield under a condensation condition applicable even to a highly rare non-natural amino acid by using an easily available condensing agent and additive capable of suppressing prematurecleavage and also suppressing a side reaction especially in a condensation reaction process of a solid phase synthesis method of a peptide.SOLUTION: Provided is a method for producing a peptide compound, including a step of condensing a first amino acid or peptide and a second amino acid or peptide in the presence of an additive and a condensing agent to obtain a condensate, wherein the number of moles of the additive is smaller than the number of moles of the second amino acid or peptide. By using a small amount of the additive with respect to the amino acid or peptide to be added to the N-terminus, the condensation reaction can be allowed to proceed efficiently even when an amino acid having large steric hindrance is contained, and the target peptide compound can be obtained with high yield and high purity.SELECTED DRAWING: None

Provided is a method for producing a peptide compound or a salt thereof, including a step (linking step) of linking an amino group of a first amino acid or peptide and a carboxy group of a second amino acid or peptide with an amide bond, wherein a stand-alone condensing agent and one or more additive(s) are used in the linking step, and the additive(s) are one or more selected from the group consisting of HOPO, HOAt, HOOBt, HOCt, PfpOH, Oxyma, Oxyma-B, N-HOSu, and K-Oxyma.

The present invention provides immunoconjugates of formula (I) comprising an antibody linked by conjugation to one or more 8-sulfonyl-2-aminobenzazepine derivatives. The present invention also provides 8-sulfonyl-2-aminobenzazepine derivative intermediate compositions comprising reactive functional groups. Such intermediate compositions are suitable substrates for the formation of the present immunoconjugates via a linker or linking moiety. The present invention further provides methods of treating cancer using the present immunoconjugates.

This invention provides novel antibody compounds and methods for using them. [Solution] Manipulated antibody compounds and their conjugates are provided, which are useful as agents for cancer immunotherapy.

The present invention provides a conjugate of an antibody and a functional substance, said conjugate having excellent desired properties, or a salt thereof. More particularly, the present invention provides a conjugate of an antibody and a functional substance, said conjugate containing a structural unit represented by formula (1) [wherein: Ig represents an immunoglobulin unit containing two heavy chains and two light chains and bonded to LA adjacent to Ig via thiol groups in the side chains of a plurality of cysteine residues in the two heavy chains and two light chains; HG represents a hydrophilic group or a monovalent group containing a hydrophilic group; CS represents a divalent group containing a cleavable moiety; ring A represents a divalent aromatic ring group which may have a substituent (wherein the divalent aromatic ring group constitutes a π-electron conjugated system together with the aforesaid cleavable moiety); V represents an oxygen atom, a sulfur atom or an amino(NH) group; LA and LB independently represent a divalent group; D represents a functional substance; and the average number n of the aforesaid bonds per immunoglobulin unit is 1.5 or more] or a salt thereof, and substances related thereto.

Peptides and Peptide-lipid conjugates are provided in which the peptide has the general Formula (I), wherein, A1 is selected from serine, threonine, O-C1-6 alkyl serine, and O-C1-6 alkyl threonine; A2 is selected from serine, threonine, O-C1-6 alkyl serine, and O-C1-6 alkyl threonine; A3 is selected from glutamic acid, glutamine, asparagine, and aspartic acid; A4 is proline; each A5 is independently selected from a natural or modified amino acid; The peptide-lipid conjugates can be used in lipid formulations for the delivery of nucleic acids.

Provided are 3-4 residue non-natural macrocyclic oligoamides comprising species of 3 or 4 monomer residues selected from the group consisting of monomers a, b, c, d, e, f, g, h, I, j, k, l, m, n, o, p, q, r, s, t, u, and v as defined in Table 1, and methods for designing such macrocyclic oligoamides.

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

Disclosed is an antibody-drug conjugate that binds to human oncology targets.The antibody-drug conjugate comprises an antibody or its antigen-binding fragment that is covalently linked to two anti-neoplastic drug payloads through a dual linker, where at least one of the anti-neoplastic drug payloads is a BH3 mimetic.The disclosure further relates to a method and composition for use in treating cancer by administering the antibody-drug conjugate provided herein.Also disclosed is a linker-drug conjugate that comprises at least one BH3 mimetic and a method for making it.

The present invention relates to a composition for skin re-pigmentation comprising a peptide inhibitor of MIA (melanoma-inhibiting activity) protein, at least one additional peptide, and a pharmaceutically acceptable excipient. The present invention also relates to the use of the composition for the prevention and / or treatment of vitiligo. The present invention also relates to the cosmetic use of the composition for skin re-pigmentation.

Provided is a coating solution for forming a cell scaffold with which a cell scaffold having a large thickness can be easily formed and the proliferation of cells can be enhanced. A coating solution for forming a cell scaffold according to the present invention contains a peptide-conjugated resin having a synthetic resin moiety and a peptide moiety and an alcohol solvent, a content of the peptide-conjugated resin being 0.1 wt% or more.

Aspects of the present invention provide polar groups, linker compounds, linker drugs, and conjugates thereof. TIFF2026503087000657.tif153145

To simply utilize a biocompatible material such as chitin or chitosan as a cell culture surface and to provide a fusion protein simply utilizable for purification and proliferation of an objective cell.SOLUTION: The present invention provides a fusion protein comprising a region consisting of at least one peptide capable of adhering to chitins and a region consisting of at least one peptide or protein capable of adhering to cells.SELECTED DRAWING: Figure 1

This invention provides a novel κ-opioid receptor (KOR receptor) agonist compound that exhibits excellent efficacy and action. [Solution] In one embodiment, a compound represented by formula IB, its stereoisomer, or a pharmaceutically acceptable salt thereof is provided. Such novel amide bond-containing compounds not only have excellent KOR receptor agonist activity (high affinity for κ opioid receptors), but also have very good hydrophilicity, and therefore have a lower ability to cross the blood-brain barrier and enter the brain. JPEG2026086406000232.jpg3368

The present invention discloses a pharmaceutical or dietary supplement composition that contains a specific combination of compounds including histidine, serine, cysteine ​​and carnosine.The composition is proposed as an ingredient in food and has been proven to be effective in treating diseases characterized by the accumulation of fat in tissues, such as fatty liver disease, obesity and atherosclerosis.

The present disclosure relates to decoy peptides. More particularly, the present disclosure provides decoy peptides comprising the comprises amino acid sequence motif of Ψ1K2X3X4, derived from proteins forming abnormal aggregates, compositions and uses thereof for treatment of proteinopathies.

The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.

The present disclosure relates to antibody drug conjugates (ADCs) comprising an antibody or antigen-binding fragment thereof covalently linked to two pharma- ceutically active drugs via a dual linker. Linker-drug conjugates comprising a dual linker and a pharma- ceutically active drug are also disclosed. Such linkers are a conventional way to deliver two (e.g., two different or the same) drugs bound to a single antibody. Such linkers may be particularly useful for improving the solubility of antibody drug conjugates (ADCs) that contain one or more hydrophobic drug compounds.

The present disclosure relates to a conjugated prodrug comprising a peptide conjugated to an antibiotic molecules via a cleavable linker and pharmaceutical compositions thereof. Also disclosed are methods of enhancing the intracellular concentration of an antibiotic agent in a bacterium and methods of treating a patient for a bacterial infection.

Aspects of the present invention disclose compounds that modulate the aggregation of amyloidogenic proteins or peptides. In some aspects, disclosed compounds modulate the aggregation of disease-associated proteins and natural β-amyloid peptides. In a preferred embodiment, the compounds can inhibit natural amyloid aggregation. Pharmaceutical compositions comprising the compounds of the embodiments, and diagnostic and treatment methods for diseases (e.g., amyloidogenic diseases) using the compounds, are also disclosed. In addition, there is provided an integrated bacterial platform for the discovery of rescuers of disease-associated protein misfolding.

The present invention generally relates to ligand-drug conjugates of Formula I: or a pharmaceutically acceptable salt, stereoisomer, or isotope thereof. The present invention further relates to the use of compounds of Formula I for the treatment of cancer. TIFF2026501817000420.tif44170

Embodiments of the disclosure include methods and compositions related to use of compound comprising a particular peptide linked to a dye. In specific embodiments, the peptide DIRG is linked to the BODIPY dye. In specific embodiments, the compositions are utilized for treatment of neurological conditions and secondary pathologies related therewith, such as spinal cord injury and Alzheimer's Disease, as examples.

The present invention relates to novel peptidomimetic (or peptoid) molecules for the prevention and / or treatment of chronic pain, in particular chronic pain resulting from peripheral neuropathy.

Provided herein are compounds (e.g., peptides) comprising a cationic alkyl moiety, compositions comprising such compounds, and methods of using such compounds to treat, for example, a disease, disorder, or pathological condition. In some embodiments, the conjugated peptide has equivalent or greater biological activity than the unmodified peptide at an equivalent bolus dose, equivalent or greater blood levels than the unconjugated peptide at the same time point after bolus administration at an equivalent dose, or a combination thereof. Provided herein are compositions comprising the compounds or conjugated peptides of this disclosure for use in the manufacture of medical compositions.

The present invention relates to the field of medicines, particularly to synthetic polyamide compounds represented by formula IB, or pharmaceutically acceptable salts and stereoisomers thereof, a composition containing same, a method for preparing same, and use thereof in the field of medicines.

Peptides have the general formula X-(Xaa) n K * TFK * -(Xaa) m -Z. The peptide serves to maintain or improve the condition of the epidermis. * is selected from lysine (K), ornithine, diaminobutyric acid or diaminopropionic acid, or hydroxylated derivatives thereof. n and (Xaa) m corresponds independently to a sequence of n or m amino acids Xaa selected independently from Gly, Ala, Pro, Val, Leu, Ile and Phe, where n and m are integers between 0 and 5, which may be equal or different. The N-terminal X is H, -CO-R 1 , -SO2-R 1 or a biotinoyl group. Z at the C-terminus is selected from OH, OR 1 , NH2, NHR 1 or NR 1 R 2 Selected from: R 1 and R 2 are independently selected from alkyl, aryl, aralkyl, alkylaryl, alkoxy, sugar and aryloxy groups, which may be linear, branched, cyclic, polycyclic, unsaturated, hydroxylated, carbonylated, phosphorylated and / or sulfurized, said groups having from 1 to 24 carbon atoms and optionally containing O, S and / or N heteroatoms in their backbone. A preferred peptide is Pal-KTFK.